These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mechanisms of lipopolysaccharide-induced protection against pseudomonas sepsis in granulocytopenic mice. Tegtmeier BR; Andersen BR Rev Infect Dis; 1983; 5 Suppl 5():S963-70. PubMed ID: 6419318 [TBL] [Abstract][Full Text] [Related]
4. Combined pre-immunization and granulocyte transfusion therapy for treatment of pseudomonas septicemia in neutropenic dogs. Harvath L; Andersen BR; Zander AR; Epstein RB J Lab Clin Med; 1976 May; 87(5):840-7. PubMed ID: 1270891 [TBL] [Abstract][Full Text] [Related]
5. Serotype-nonspecific protection induced by ribonucleic acid isolated from the ribosomal vaccine of Pseudomonas aeruginosa. Gonggrijp R; Mullers WJ; van Boven CP Infect Immun; 1981 Jul; 33(1):178-85. PubMed ID: 6167518 [TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of a polyvalent corpuscular Pseudomonas aeruginosa vaccine, antibiotics and their combinations in experimental chronic Pseudomonas aeruginosa infection]. Vetkova LG; Antsiferova NG; Radkevich SA; Moroz AF Zh Mikrobiol Epidemiol Immunobiol; 1985 Mar; (3):51-6. PubMed ID: 3922187 [TBL] [Abstract][Full Text] [Related]
7. Pseudomonas septicemia in neutropenic dogs. I. Treatment with granulocyte transfusions. Epstein RB; Waxman FJ; Bennett BT; Andersen BR Transfusion; 1974; 14(1):51-7. PubMed ID: 4204585 [No Abstract] [Full Text] [Related]
8. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection. Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634 [TBL] [Abstract][Full Text] [Related]
9. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine]. Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165 [TBL] [Abstract][Full Text] [Related]
10. [Dynamics of the contamination of mice during the treatment of burn sepsis due to Pseudomonas aeruginosa using tobramycin alone or combined with active and passive immunization]. Minukhin VV; Tsyganenko AIa Zh Mikrobiol Epidemiol Immunobiol; 1986 Sep; (9):90-2. PubMed ID: 3098009 [TBL] [Abstract][Full Text] [Related]
12. [Protective effect of a corpuscular polyvalent Pseudomonas aeruginosa vaccine in generalized chronic Pseudomonas aeruginosa infection in mice with cyclophosphamide-induced leukopenia]. Vetkova LG; Zaĭtsev LG; Khasman EL; Radkevich SA; Moroz AF Zh Mikrobiol Epidemiol Immunobiol; 1986 Mar; (3):14-8. PubMed ID: 3085409 [TBL] [Abstract][Full Text] [Related]
13. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346 [TBL] [Abstract][Full Text] [Related]
14. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100 [TBL] [Abstract][Full Text] [Related]
15. Determination of type specific IgG Pseudomonas antibodies by the ELISA test after administration of the anti Pseudomonas aeruginosa vaccine. Meitert T; Meitert E; Pencu E; Tonciu M Arch Roum Pathol Exp Microbiol; 1984; 43(1):53-60. PubMed ID: 6442132 [No Abstract] [Full Text] [Related]
16. [Experimental basis for the combined use of tobramycin and immune preparations for treating acute Pseudomonas aeruginosa infections]. Minukhin VV; Tsyganenko VIa Zh Mikrobiol Epidemiol Immunobiol; 1986 Aug; (8):42-5. PubMed ID: 3094301 [TBL] [Abstract][Full Text] [Related]
17. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa. Mates A; Zand P J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979 [TBL] [Abstract][Full Text] [Related]
18. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection. Okada K; Kawaharajo K; Kasai T; Homma JY Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131 [TBL] [Abstract][Full Text] [Related]
20. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine. Jones RJ; Roe EA Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]